Transforming the Treatment of Neuromuscular Diseases with Next-Gen Oligonucleotides

James McArthur, president and CEO of PepGen, discusses the company’s platform technology for conjugating oligonucleotides with peptides, how this allows it to target hard to reach tissue, and why it opens the potential for new therapies to treat neuromuscular and other diseases.